Latest Erlotinib Stories
WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Biotech Showcase 2011 on Tuesday, January 11, 2011 at 10:00 a.m.
A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC).
Combining epigenetic therapy and molecular targeted therapy has shown promising results for combating advanced lung cancer.
WALTHAM, Mass., Dec.
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer.
RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs.
WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC).
BURLINGTON, Mass., Dec.
A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.
NASHVILLE, Tenn. and GLEN ROCK, N.J., Nov.
- Large; stout; burly.